There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Axl


Axl Molecule Information

Name:AXL receptor tyrosine kinase
Target Synonym:AXL oncogene;AXL Receptor Tyrosine Kinase;AXL;UFO;Tyrosine-protein kinase receptor UFO
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Axl Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AXL-C52H3 Cynomolgus Cynomolgus Axl Protein, His Tag
AXL-H5226 Human Human Axl Protein, His Tag

Axl Molecule Synonym Name


Axl Molecule Background

AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.

Axl References

Axl Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gilteritinib fumarate ASP-2215; ASP-2215 hemifumarate; 66D-92MGC8M (UNII code) Approved Astellas Gilteritinib fumarate 日本 Acute myeloid Leukemia (AML) 安斯泰来 2018-09-21 00:00:00.0 Acute myeloid Leukemia (AML) Details
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details

Axl Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ONO-7475 ONO-7475 Phase Ⅰ Ono Pharmaceutical Acute myeloid Leukemia (AML) Details
LDC-1267 LDC-1267 Preclinical Max Planck Innovation, Lead Discovery Center Cancer Details
BA-3011 BA-3011 Phase Ⅱ BioAtla, Sinobioway Biomedicine Solid tumours Details
Enapotamab vedotin (Genmab) AXL-107-MMAE Phase Ⅱ Genmab, Seattle Genetics Solid tumours Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase Ⅱ HEC Pharm Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), Renal carcinoma Details
INCB-081776 INCB-081776; INCB-81776 Phase Ⅰ Incyte Solid tumours Details
Bemcentinib BGB-324; R-428,BGB324; R428,BGB 324; R 428 Phase Ⅱ Rigel, BerGenBio, Merck Sharp & Dohme Myelodysplastic syndrome (MDS), Non small cell lung cancer (NSCLC), Breast cancer, Acute myeloid Leukemia (AML), Idiopathic pulmonary fibrosis (IPF), Non-alcoholic steatohepatitis, Pancreatic cancer, Chronic myeloid leukemia (CML ), Melanoma Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 IND Filing Shijiazhuang No.4 Pharmaceutical, Nanjing Nadingfei Medical Technology Gastric cancer, Prostate cancer, Lung cancer, Liver cancer Details
Dubermatinib TP-0903 Phase Ⅱ Sumitomo Dainippon Chronic lymphocytic leukemia (CLL) Details
SLC-391 SLC-391 Phase Ⅰ SignalChem Lifesciences Solid tumours Details
ADCT-601 ADCT-601,ADCT 601,ADCT601 Phase Ⅰ ADC Therapeutics Solid tumours Details
RXDX-106 RXDX-106 Phase Ⅰ Teva, Daiichi Sankyo, Roche Solid tumours Details
BGB-149 BGB-149 Phase Ⅰ BerGenBio Cancer Details
BPI-9016 BPI-9016M; BPI-9016 Phase Ⅰ Betta Non small cell lung cancer (NSCLC) Details
DS-1205 (Daiichi Sankyo Company) DS-1205; DS-1205b; DS-1205c Phase Ⅰ Daiichi Sankyo Non small cell lung cancer (NSCLC) Details
S-49076 S-49076,S49076 Phase Ⅱ Servier Non small cell lung cancer (NSCLC), Glioblastoma Details

This web search service is supported by Google Inc.